A complex M&A transaction

A large diversified pharmaceutical firm wished to evaluate the risks and rewards of a potential large drug-licensing deal. The complicating factor was that the proposed M&A contract allowed either of the two parties involved to change the business terms, after the deal would be signed (i.e. ‘flip’ the terms).

EpiX Analytics provided strategic advice and constructed a Monte Carlo simulation model that captured the medical and financial risks of the drugs as well as the “optionality” within the potential M&A deal-terms.

The results of the model allowed the client to take a more favorable negotiation strategy which resulted in a successful licensing deal.

Back to all case studies


We believe in seeing to believe.

View our client success stories to read about our projects.


Once in a while, we ask our clients, course participants and co-investigators to provide us with testimonials of their experience working with us. Read what they're saying about us.

Brief History of EpiX Analytics

EpiX Analytics was founded in 2003 in Princeton, NJ under the Vose Consulting name, and among its offerings it included specialized software to perform Monte Carlo simulations. Read More >>